These selective Fcs are designed for (i) tumor cell destruction, such as anti-CD20 antibodies [5], (ii) immune cell activation, such as agonistic anti-CD40 [107,108] or anti-TNFR antibodies [109], which elicit antigen presentation and subsequent adaptive immune response by engaging FcγRIIb, and (iii) anti-tumor vaccine effect [92]. Here, TNFRSF1A is linked to neoplasm.